Mass Spectrometry is key technology for studying critical molecules and pathways. Defining molecular targets is crucial for the process of drug development.
In our group, we are focused on using proteomics, mass spectrometry and biochemical approaches to understand disease processes.
The group has expertise in proteomics based methodologies and hosts a platform containing a variety of chromatography equipment and mass spectrometers.
Kessler Group Sky Garden London Nov 2018
- For Non-Scientists
- Research Overview
- Mass Spectrometry
- Public Engagement
- Photo Gallery
- Virtual tour of the Kessler Lab
- Former Group Members
The Bloom syndrome complex senses RPA-coated single-stranded DNA to restart stalled replication forks
Shorrocks A-MK. et al, (2021), Nature Communications, 12
Phenotypic manifestation of α-synuclein strains derived from Parkinson’s disease and multiple system atrophy in human dopaminergic neurons
Tanudjojo B. et al, (2021), Nature Communications, 12
Inflammasome activation controlled by the interplay between post-translational modifications: emerging drug target opportunities
Liang Z. et al, (2021), Cell Communication and Signaling, 19
Advancing Mechanistic Understanding and Biomarker Development in Amyotrophic Lateral Sclerosis.
Thompson AG. et al, (2021), Expert Rev Proteomics
Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection.
Munnur D. et al, (2021), Nat Immunol